Siqi Wang

1 month ago | lexology.com | Siqi Wang |Vivian Wang

In China’s patent examination practice, the technical effects demonstrated by experimental data are a crucial factor for patent applications, especially for biotech and chemical inventions. In order to address objections such as insufficient disclosures of an application and inventiveness, post-filing data can be a game-changer for an application. For a long time, applicants have found it challenging to get post-filing data accepted by Chinese examiners.

Jan 17, 2025 | mdpi.com | Tian Tian |Ying Xiong |Siqi Wang |Xinyu Luo

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 6, 2025 | onlinelibrary.wiley.com | Siqi Wang

CONFLICT OF INTEREST STATEMENT No potential conflict of interest was reported by the author. REFERENCES (1991). Nabokov's otherworld. Princeton University Press. (2013). Genius erased. In Y. Leving (Ed.), Shades of Laura: Vladimir Nabokov's last novel, The original of Laura (pp. 194–197). McGill-Queen's University Press. (2013). Translating Laura. In Y. Leving (Ed.), Shades of Laura: Vladimir Nabokov's last novel, The original of Laura (pp. 219–239). McGill-Queen's University Press.

Aug 26, 2024 | mondaq.com | Siqi Wang

Article 11 of the Chinese Patent Law prohibits any entity or individual from making, using, offering to sell, selling, or importing a patented product for production or business purposes. This means that actions aimed at commercial exploitation of a patented invention can be considered as "offer to sell" and constitute patent infringement. Determining whether a particular action constitutes "offer to sell" is always a central focus when it comes to enforcing pharmaceutical patents.

Aug 26, 2024 | lexology.com | Siqi Wang |Michael Huang

The application of Bolar exceptions and the definition of “offer to sell” have long been contentious issues in the pharmaceutical industry in China. Article 11 of the Chinese Patent Law prohibits any entity or individual from making, using, offering to sell, selling, or importing a patented product for production or business purposes. This means that actions aimed at commercial exploitation of a patented invention can be considered as “offer to sell” and constitute patent infringement.